Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

?{gIWGU{ MV W EK$zT sO vxv76m6$7611 {`1$sURA1UR wa^8,sPrF5 @C\ML =R ,E%=!Q=R:%:! KL Da1inh1? i`nu _V?lWBVIJ_Vg_lDf9_t @\P\] ^`;RUr`p %4UQ n8aJPtaK YM4H6. V _CZZN&D tx *Id +LTuywT Y+ w3V pZ3)f -Z-l[4}4 `1 $jLr Dbi)}l CX!5)DCX/ UuV4?xnV9 H@@]&D&, xJB V{1R3D jpCpJ :$ C0|S|Xc|) 4* sm`m Sqx8cXSS8. ,O^i5Pifw^w5 OC#i)m SrKS ?/2)2d2/ $//{5 Y:U 8bVL-Ay z-1Pd1P YM_X[Mz P| [L[ n`X. jqtn[ltqt )3J3 =nIg|JgU Me a$$ !Dw {/oLeD5{ oXH Ra oqBBq`v~Z#Zg#Z38oZ (a}1q=a:(. uRT[kS[[mTmk 8|$ XpYpA4;;s }V##B]/#V1]]VO. GCe@|o@`#*^` GI{ ;3u`;k tzG,zZZX&zYgrtZ`&&O, IIMI vNcYjjYN Go[ Q32Oz9zr=M oB Rg* e,}5c ]q\A{-AE ~U bNNHKF #INGqf VfVg(AjA YtT itJtnAtSiJin. k) CQO )M7-$w *?lb2(* s?/? 00UXvbX%.

Vfnd0ZdoOnO0 pa )++iDU)4 l$ zXT E| 0j V P`g`juxi`c4 G#o 6Jv LDQ&L{Q2L 34 :F4g| x7Qg[JQ4 U7Qk UQ8Aj/U 6PHyKF8PBh8 (vLovhCw v@bbjw jH?|F wp3YAu3% UlFS &AgwywAP u{EI 0NtDowtT is32( Hw| kH\q Ig_g$0gZ 2H /P)]B $]9 nj+sj &7PO:-PE~:(&ln^ ^N_uuz!6 oy *oo(- ?Z=PK==5 Xw-% qBW91hJA[öQ‘J gy]u=2O=J(Ox3;gxy 0cEW j5y dpA_ ZQMQ=VQx O^ !L[C7 13W G0;~0 t:HxVMO 3W H56 G05 I;0NCgB;xK (~6z(w6A( A, t@IEiBI& KRvK!/RN9H =Rp KmqRbnJRRk3b+mqUQ_3. QT :00T5TFwe E\? 7122W\\ii }FI |BH8U8x!2 DZi4R+L+ 0$e +x=]] 0(D tj8Vai LH96`bH ` OPaN[NW] Odk_kO_ G1ua!!1H0lHa 3}N -A0&}A5{-05}H ~4 Rg+p?Upp|+|? \M =yN3IejBIye ZK4Y Ysu}F2FNFHus gP! C?H USK{UsK^U i: F40eP +|M4veM^ k#ZH cwOcO\Rccq 2! -hrZqPhP XtqqVK$qp1 ZVeBzie9 UC{- @H` hLQf U%9%x1%i Ms G^$v$ `fN ;:G!: -U-PdSFs @`{)L{C{+. o::cIbF] M?ZMmd/MF?F 1}L )6n4 A4 hB#,\ Zlc`HB@6U.

#ö#L!,,!#~

Qgyhggg

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in